Evolent Health
EVH
243 hedge funds and large institutions have $2.48B invested in Evolent Health in 2024 Q2 according to their latest regulatory filings, with 45 funds opening new positions, 102 increasing their positions, 74 reducing their positions, and 51 closing their positions.
38% more repeat investments, than reductions
Existing positions increased: 102 | Existing positions reduced: 74
2.54% more ownership
Funds ownership: 109.03% → 111.57% (+2.5%)
3% less funds holding
Funds holding: 251 → 243 (-8)
12% less first-time investments, than exits
New positions opened: 45 | Existing positions closed: 51
40% less capital invested
Capital invested by funds: $4.12B → $2.48B (-$1.65B)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
58% less call options, than puts
Call options by funds: $10.5M | Put options by funds: $25.1M
Top Buyers
Top Sellers
EVH Hedge Fund Activity: Q2 2024 in Review
243 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q2 2024, worth a combined $2.48B — down 40% from $4.12B a quarter earlier.
Sellers outnumbered buyers: 51 funds closed out of EVH and 45 opened new positions — a net loss of 6 holders — while 74 trimmed existing stakes and 102 added.
The largest buyer was RA Capital Management, adding an estimated $71M. The largest seller was Fidelity Investments, cutting an estimated $114M.
- 243 institutional investors held Evolent Health (EVH) as of Q2 2024, down from 251 in Q1 2024.
- Funds reported $2.48B of Evolent Health stock for Q2 2024, down 40% quarter-over-quarter.
- 45 funds opened new Evolent Health positions in Q2 2024 and 51 closed out, a net change of -6 holders.
- The largest Evolent Health buyer in Q2 2024 was RA Capital Management, an estimated $71M added.
- The largest Evolent Health seller in Q2 2024 was Fidelity Investments, an estimated $114M sold.
Based on aggregated 13F filings for Q2 2024.